Key Highlights

  • TRAX closed up 13.70% at $41.25 on October 20, up 22.33% over the week and 2.62% over the month, with a market capitalization of about $1.48 billion.
  • The company priced a $200 million private placement of 6,106,870 shares at $32.75 on October 15.
  • The offering price sits about 21% below the October 20 close.
  • Cash was $168.0 million at June 30, down from $311.6 million at the end of 2025.
  • First celiac cohort data for ANB033 are expected in the fourth quarter of 2026.

Why Is First Tracks Biotherapeutics Stock Up 22% This Week, and What Is Being Missed?

First Tracks Biotherapeutics (NASDAQ:TRAX) closed up 13.70% at $41.25 on October 20 and is up 22.33% over the week, against a gain of only 2.62% over the past month. The market capitalization is about $1.48 billion. The week's rally coincides with an October 15 announcement of a second private placement, which is the main fact investors may be overlooking.

The company agreed to sell 6,106,870 shares at $32.75, raising about $200 million gross, with closing expected on October 19. The closing could not be confirmed. A resale registration is to follow, its timing was not stated, and it leaves the possibility of future share supply. The offering price sits about 21% below the October 20 close.

How Did the Spin-Off and Earlier Placement Set the Price Path?

First Tracks is a San Diego clinical-stage company developing antibodies for autoimmune and inflammatory disease. It was spun off from AnaptysBio (NASDAQ:ANAB) on April 20, 2026, when 29,100,902 shares were distributed one for one to AnaptysBio holders.

A concurrent private placement sold 5,791,479 new shares at $13.81 for about $80 million, plus 4,705,575 shares sold by an existing holder. At $41.25, the stock trades at about three times that placement price.

Shares outstanding were 35,730,843 at August 7, before the new placement was added.

What Do First Tracks's Cash and Losses Show Before the New Money?

Second-quarter results released on August 12 showed cash of $168.0 million at June 30, down from $311.6 million at the end of 2025. The net loss was $33.4 million, or $0.95 per share. Research and development expenses were $25.6 million, and general and administrative expenses were $9.3 million.

The company said cash funded operations into the second quarter of 2028 before the new placement. The roughly $200 million of gross proceeds, if the closing is confirmed, would be added to that base.

Which Clinical Readouts Are Next for First Tracks's ANB033 and Other Programs?

The lead program, ANB033, is a CD122 antagonist with Fast Track designation in celiac disease. Data from the first celiac cohort, a gluten challenge, are expected in the fourth quarter of 2026, and mucosal healing data from the second cohort in the first quarter of 2027.

Phase 1b data in eosinophilic esophagitis are expected in the third quarter of 2027. Phase 2 studies in two more indications are due to start in the first half of 2027.

Rosnilimab in rheumatoid arthritis completed an end-of-Phase 2 meeting in the first quarter of 2026, and the company is assessing strategic options with no dates given. The BDCA2 antibody ANB101 has completed a Phase 1a study.

The first celiac cohort in the fourth quarter is the next hard clinical data point, and confirmation that the placement closed is the near-term item to check. At $41.25, the stock sits well above the $32.75 placement price.